Ashkan Shoamanesh: FDA Grants Asundexian A Priority Review for Secondary Stroke Prevention
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”Excellent news for patients with ischemic stroke and high-risk TIA: the U.S. FDA has granted Priority Review to asundexian for secondary stroke prevention based on the results of the OCEANIC-STROKE trial.
This marks an important step toward the potential rapid availability of a novel treatment strategy aimed at reducing recurrent ischemic events without increasing major bleeding risk – a long-standing unmet need in stroke prevention.
Very hopeful that other global regulatory agencies will follow suit so that patients worldwide may benefit from timely access to this therapy.”
Stay updated on all scientific advances with Hemostasis Today.
-
May 21, 2026, 06:55Hayley Evans: Scaling PBM Quality Improvement Through Automated TXA Tracking
-
May 21, 2026, 06:49Erwin Loh: Higher-Than-Recommended Physical Activity Levels Linked to Greater Reduction in Heart Attack and Stroke Risk
-
May 21, 2026, 04:54Enrico Ferro: Thank You Niraj Sharma for Covering Our AFib Ablation Stroke Safety Analysis
-
May 21, 2026, 04:38Luca Bonanni: How Mesenchymal Stromal Cells Interact With Coagulation and Innate Immunity
-
May 21, 2026, 04:27Anirban Sen Gupta: Congratulations to Solomon Oshabaheebwa on His PhD Defense in Microfluidic Diagnostics for SCD
-
May 21, 2026, 02:25Claudio Laudani: A Striking Geographic Heterogeneity in Aspirin and Clopidogrel Comparison for MACE Prevention
-
May 20, 2026, 17:10Applications are Now Open for the Fellowship in Clinical Haematology – Apollo Hospitals Navi Mumbai
-
May 20, 2026, 17:02Samantha Pasca and Deanna Maida on the Importance of Registries in Managing Hemophilia in Women
-
May 20, 2026, 16:48New Clinical Resources for Stroke Prevention – Anticoagulation Forum